How to Get Zetia (Ezetimibe) in Colorado

Who Can Prescribe Ezetimibe in Colorado

Any prescriber holding an active Colorado medical license can write a prescription for ezetimibe. That includes physicians (MD and DO), nurse practitioners, and physician assistants. Colorado grants NPs full practice authority under the Nurse Practice Act, meaning NPs do not need a collaborative physician agreement to prescribe non-controlled medications like ezetimibe.

MDs and DOs

Board-certified internists, family medicine physicians, and cardiologists are the most common prescribers. A lipid panel showing elevated LDL cholesterol (typically above 70 mg/dL for high-risk patients or above 100 mg/dL for moderate-risk patients) is the standard starting point. Most Colorado physicians follow the 2018 ACC/AHA Cholesterol Guideline, which recommends ezetimibe as add-on therapy when maximally tolerated statin therapy fails to achieve a 50% LDL reduction.

Nurse Practitioners and Physician Assistants

NPs and PAs in Colorado can independently evaluate lipid panels, diagnose hyperlipidemia, and prescribe ezetimibe. This matters in rural counties like Moffat, San Juan, and Mineral, where NP-staffed clinics may be the nearest prescribing option. PAs practice under a collaborative agreement with a supervising physician per Colorado Revised Statutes 12-240-107, but this does not restrict their authority to prescribe ezetimibe.

Telehealth Prescribers

Colorado's telehealth parity law (SB 20-212) requires insurers to reimburse telehealth visits at the same rate as in-person visits. Prescribers licensed in Colorado can evaluate a patient via synchronous video, review uploaded lab results, and transmit an ezetimibe prescription electronically to any Colorado pharmacy. No in-person visit is required for the initial prescription.

Telehealth Access for Ezetimibe in Colorado

Telehealth is a practical route to an ezetimibe prescription, especially for patients in the 47 of Colorado's 64 counties classified as rural or frontier by the Colorado Rural Health Center.

How a Telehealth Visit Works

A typical telehealth ezetimibe consultation takes 10 to 20 minutes. The prescriber reviews your most recent lipid panel (a fasting panel drawn within the past 12 months is standard), your statin history, and any documented statin intolerance. If your LDL remains above goal on a maximally tolerated statin, or if you cannot tolerate statins at all, ezetimibe is a first-line non-statin option per the ACC/AHA guideline.

What You Need Before the Visit

Arrive with three things: a recent lipid panel, a list of current medications, and documentation of any prior statin trials. If you have not had bloodwork in over 12 months, most telehealth platforms will order labs at a local Quest Diagnostics or Labcorp draw site before scheduling the prescribing visit. Colorado has 78 Quest Diagnostics and 52 Labcorp patient service centers statewide.

Prescription Delivery Timeline

After the telehealth visit, the prescriber sends the e-prescription directly to your chosen pharmacy. Most patients pick up ezetimibe same-day or next-day at a retail pharmacy. Mail-order pharmacies typically deliver within 3 to 5 business days to Colorado addresses, including mountain communities.

Labs Required Before and During Ezetimibe Therapy

Ezetimibe has a favorable safety profile, but Colorado prescribers follow standard monitoring protocols aligned with the FDA-approved prescribing information.

Baseline Labs

Before starting ezetimibe, your prescriber will order a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) and a hepatic function panel. The liver panel matters because ezetimibe combined with a statin carries a low but measurable risk of transaminase elevation. In the IMPROVE-IT trial (N=18,144), the rate of consecutive ALT/AST elevations greater than three times the upper limit of normal was 2.5% in the ezetimibe-simvastatin group versus 2.3% in simvastatin alone, a clinically insignificant difference.

Follow-Up Monitoring

A repeat lipid panel at 6 to 8 weeks confirms response. Ezetimibe 10 mg lowers LDL-C by approximately 18% as monotherapy and by an additional 23 to 24% when added to a statin, based on pooled data from 12 randomized controlled trials. After confirming response, annual lipid panels and periodic hepatic function panels suffice for ongoing monitoring. No routine CK (creatine kinase) monitoring is needed for ezetimibe monotherapy.

Colorado Medicaid and Insurance Coverage

This is where Colorado access gets complicated. Coverage depends heavily on the indication and the insurance type.

Colorado Medicaid Limitations

Colorado Medicaid (Health First Colorado) covers ezetimibe only when prescribed for type 2 diabetes with dyslipidemia. It is not covered as a standalone hyperlipidemia adjunct. This means a Medicaid enrollee with primary hypercholesterolemia and no diabetes diagnosis will face a denial. The workaround is limited: the prescriber must document the clinical rationale and submit a prior authorization, but approvals for off-formulary use in this scenario are uncommon.

Commercial Insurance

Most commercial plans in Colorado (Anthem, Cigna, UnitedHealthcare, Kaiser Permanente of Colorado) cover generic ezetimibe on Tier 1 or Tier 2 formularies with copays between $5 and $20. Brand-name Zetia, when specifically requested, usually sits on Tier 3 with copays of $35 to $75. The 2018 ACC/AHA guideline recommends ezetimibe for patients who do not achieve adequate LDL reduction on maximally tolerated statin therapy, and most commercial payers align their coverage criteria with this recommendation.

Prior Authorization Requirements

Some commercial plans require prior authorization when ezetimibe is prescribed as monotherapy (without a concurrent statin). The documentation typically needed includes:

• A recent lipid panel showing LDL above goal
• Documentation of statin intolerance (specific statin names, doses tried, adverse effects experienced)
• The prescriber's clinical rationale for ezetimibe monotherapy

Processing time for prior authorizations in Colorado averages 48 to 72 hours for commercial plans. Colorado law (CRS 10-16-112.5) requires health plans to respond to standard prior authorization requests within 5 business days and urgent requests within 24 hours.

Cash-Pay and Discount Options

Generic ezetimibe is one of the most affordable cholesterol medications on the market. GoodRx and similar platforms show 30-tablet supplies at $8 to $15 at Walmart, Costco, and King Soopers pharmacies across Colorado. Costco does not require a membership for pharmacy purchases. For patients facing insurance denials, cash pay is often cheaper than appealing the denial.

Colorado Pharmacy Options

Ezetimibe is widely stocked at retail pharmacies across Colorado. No specialty pharmacy or cold-chain handling is required.

Retail Chains

King Soopers (Kroger), Walgreens, CVS, Walmart, Safeway, and Costco all carry generic ezetimibe. Colorado has over 1,200 licensed retail pharmacies according to the Colorado State Board of Pharmacy. Even small mountain-town pharmacies in places like Glenwood Springs, Durango, and Steamboat Springs stock this medication routinely.

503A Compounding Pharmacies

Colorado licenses 503A compounding pharmacies that can prepare ezetimibe in alternative dosage forms (such as suspensions for patients with swallowing difficulties). These pharmacies operate under a patient-specific prescription and can ship within Colorado. A 503A pharmacy cannot distribute ezetimibe without a valid prescription from a Colorado-licensed prescriber. This option is niche but relevant for patients who cannot swallow tablets.

Mail-Order Pharmacies

Express Scripts, CVS Caremark, and OptumRx all ship generic ezetimibe to Colorado addresses. Mail-order typically offers a 90-day supply at a lower per-unit cost than retail. Delivery times run 3 to 7 business days to Front Range addresses and 5 to 10 business days to Western Slope locations during winter months.

Transferring an Ezetimibe Prescription to Colorado

If you are moving to Colorado or splitting time between states, transferring your prescription is straightforward.

Within-State Transfers

Colorado pharmacies can transfer prescriptions between locations with a pharmacist-to-pharmacist call. Walk into your new pharmacy, provide your name and date of birth, and the receiving pharmacist will contact the transferring pharmacy directly.

Out-of-State Transfers

Colorado accepts prescription transfers from any U.S. State for non-controlled medications like ezetimibe. Your new Colorado pharmacy contacts the out-of-state pharmacy, verifies the prescription details, and processes the transfer. The prescriber does not need to be re-involved unless the prescription has expired. In Colorado, prescriptions for non-controlled medications are valid for one year from the date written.

New Prescriber, Same Medication

If your out-of-state prescriber is not licensed in Colorado, you will need a new prescription from a Colorado-licensed provider. A telehealth visit with uploaded records from your previous prescriber is the fastest route. Bring your prior lipid panels and medication history.

Clinical Evidence Supporting Ezetimibe Access

The evidence base for ezetimibe is strong, anchored by one of the largest cardiovascular outcomes trials ever conducted.

IMPROVE-IT Trial

The IMPROVE-IT trial, published in the New England Journal of Medicine in 2015, randomized 18,144 patients with recent acute coronary syndrome to ezetimibe 10 mg plus simvastatin 40 mg versus simvastatin 40 mg alone. At 7 years, the combination group had a 32.7% rate of the primary composite endpoint (cardiovascular death, major coronary events, or stroke) compared with 34.7% in the simvastatin-only group. That 2.0 percentage point absolute reduction (P=0.016) translated to a number needed to treat of 50.

Dr. Christopher Cannon, lead investigator of IMPROVE-IT, stated: "This trial proved that lowering LDL cholesterol below previous targets with a non-statin agent produces meaningful reductions in cardiovascular events."

ACC/AHA Guideline Position

The 2018 ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol gives ezetimibe a Class I recommendation (Level of Evidence: B-R) for patients with clinical atherosclerotic cardiovascular disease on maximally tolerated statin therapy whose LDL-C remains at or above 70 mg/dL. The guideline specifically recommends ezetimibe before PCSK9 inhibitors due to its oral route, lower cost, and established safety data.

The American Heart Association's 2019 update reinforced this positioning, noting that ezetimibe "provides an inexpensive, well-tolerated option for incremental LDL-C reduction."

Safety Profile

Ezetimibe has been on the market since FDA approval in 2002. Over 20 years of post-marketing surveillance have confirmed its tolerability. Common side effects include upper respiratory tract infection (4.3%), diarrhea (4.1%), and arthralgia (3.0%), rates that were comparable to placebo in registration trials. There are no boxed warnings. The drug is Category C in pregnancy (animal studies show risk, no adequate human studies), so it should not be prescribed to pregnant patients.

Cost Breakdown for Colorado Patients

Ezetimibe's affordability is a meaningful advantage over newer cholesterol-lowering agents.

Generic vs. Brand Pricing

Generic ezetimibe 10 mg runs $8 to $25 for a 30-day supply at Colorado retail pharmacies. Brand Zetia, when available, costs $350 to $400 per month without insurance. There is no clinical reason to choose brand over generic; the FDA's Abbreviated New Drug Application process requires bioequivalence testing confirming identical absorption and efficacy.

Comparison to Other Non-Statin Options

PCSK9 inhibitors (evolocumab, alirocumab) cost $400 to $600 per month even after recent price reductions. Bempedoic acid (Nexletol) runs $350 to $500 monthly. Inclisiran (Leqvio) costs approximately $3,250 per injection administered every 6 months. Generic ezetimibe at under $25 per month is the most cost-effective non-statin LDL-lowering option available to Colorado patients, a factor the ACC/AHA guideline explicitly acknowledges in its treatment algorithm.